Arch Venture Fund XII Updates Neumora Holdings Filing
Ticker: NMRA · Form: SC 13D/A · Filed: Nov 22, 2024 · CIK: 1885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | SC 13D/A |
| Filed Date | Nov 22, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, ownership-update, venture-capital
Related Tickers: NMRA
TL;DR
Arch Venture Fund XII group updated their Neumora filing, no new shares bought but ownership structure clarified.
AI Summary
On November 22, 2024, ARCH Venture Fund XII, L.P. and its affiliates filed an SC 13D/A amendment regarding their holdings in Neumora Therapeutics, Inc. The filing indicates a change in the group members and their reporting obligations for the subject company. The filing does not disclose specific dollar amounts or new share acquisitions but updates the list of entities involved in the reporting group.
Why It Matters
This filing clarifies the reporting structure for a significant investment group in Neumora Therapeutics, Inc., which is important for understanding ownership and potential influence on the company's strategic direction.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous filing and primarily updates group member information, not indicating a new aggressive stake or sale.
Key Players & Entities
- ARCH Venture Fund XII, L.P. (company) — Filer
- Neumora Therapeutics, Inc. (company) — Subject Company
- ARCH Venture Fund VII, L.P. (company) — Group Member
- ARCH Venture Fund VIII Overage, L.P. (company) — Group Member
- ARCH Venture Fund X Overage, L.P. (company) — Group Member
- ARCH Venture Fund X, L.P. (company) — Group Member
- ARCH Venture Partners VII, L.P. (company) — Group Member
- ARCH Venture Partners VII, LLC (company) — Group Member
- ARCH Venture Partners VIII, LLC (company) — Group Member
- ARCH Venture Partners X Overage, L.P. (company) — Group Member
FAQ
What is the primary purpose of this SC 13D/A filing?
The primary purpose is to amend the previous SC 13D filing to update the list of group members and their reporting obligations concerning Neumora Therapeutics, Inc.
Who is the primary filer in this amendment?
ARCH Venture Fund XII, L.P. is listed as the filer, along with its group members.
When was this amendment filed with the SEC?
This amendment was filed on November 22, 2024.
Does this filing indicate a new purchase of Neumora Therapeutics, Inc. shares?
The filing does not explicitly state a new purchase of shares; it focuses on updating the reporting group and their associated information.
What is the business address of Neumora Therapeutics, Inc. according to this filing?
The business address of Neumora Therapeutics, Inc. is 490 Arsenal Way, Suite 200, Watertown, MA 02472.
Filing Stats: 4,853 words · 19 min read · ~16 pages · Grade level 14.4 · Accepted 2024-11-22 17:33:43
Key Financial Figures
- $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securiti
Filing Documents
- arch-sch13d_18910.htm (SC 13D/A) — 631KB
- 0001072613-24-000899.txt ( ) — 633KB
Security
Item 1. Security and Issuer . This Amendment No. 2 (the “Amendment No. 2”) to the Schedule 13D filed on September 29, 2023 (the “Original 13D”), related to the Common Stock, $0.0001 par value per share (the “Common Stock”), of Neumora Therapeutics, Inc. (the “Issuer”) having its principal executive office at 490 Arsenal Way, Suite 200, Watertown, Massachusetts, 02472.
IDENTITY
Item 2. IDENTITY AND BACKGROUND . (a) This statement is being filed by (1) ARCH Venture Fund VII, L.P. (“AVF VII”), (2) ARCH Venture Partners VII, L.P. (“AVP VII”) which is the sole general partner of AVF VII, (3) ARCH Venture Partners VII, LLC (“AVP VII LLC”) which is the sole general partner of AVP VII, (4) ARCH Venture Fund VIII Overage, L.P. (“AVF VIII Overage”), (5) ARCH Venture Partners VIII, LLC (“AVP VIII LLC”) which is the sole general partner of AVF VIII Overage, (6) ARCH Venture Fund X, L.P. (“AVF X”), (7) ARCH Venture Partners X, L.P. (“AVP X LP”) which is the sole general partner of AVF X, (8) ARCH Venture Partners X, LLC (“AVP X LLC”) which is the sole general partner of AVP X LP and AVP X Overage LP (defined below), (9) ARCH Venture Fund X Overage, L.P. (“AVF X Overage”), (10) ARCH Venture Partners X Overage, L.P. (“AVP X Overage LP”), which is the sole general partner of AVF X Overage, (11) ARCH Venture Fund XII, L.P. (“AVF XII”), (12) ARCH Venture Partners XII, L.P. (“AVP XII LP”) which is the sole general partner of AVF XII, (13) ARCH Venture Partners XII, LLC (“AVP XII LLC”) which is the sole general partner of AVF XII, (13) Keith Crandell (“Crandell”), (14) Robert Nelsen (“Nelsen”), (15) Clinton Bybee (“Bybee”, and together with Nelsen and Crandell, referred to individually as a Managing Director or collectively as the “AVP VII Managing Directors”, “AVP VIII Managing Directors” or “Managing Directors”, (16) Kristina Burow (“Burow”), and (17) Steven Gillis (“Gillis”, and together with Nelsen, Crandell and Burow, referred to individually as “Committee Member” or collectively as either the “AVP X Investment Committee Members” or the “AVP XII Investment Committee Members&
Material
Item 7. Material to be Filed as Exhibits . Exhibit 1- Agreement of Joint Filing Exhibit 2- Agreement of Joint Filing Exhibit 3- Agreement of Joint Filing Exhibit 4- Agreement of Joint Filing Exhibit 5- Amended and Restated Investors’ Rights Agreement, dated September 22, 2022, as amended, by and among the Issuer and certain of its stockholders (incorporated by reference to Exhibit 10.1 to the Issuer’s Registration Statement on Form S-1 (File No. 333-274229), as filed with the Securities and Exchange Commission on August 25, 2023) CUSIP No. 640979 100 13D Page 23 of 32 Pages Signatu